Antibody-Antigen Engineering Research Group
The increasing development of biotechnology has laid the ground to achieve modern technologies and improve their efficacy. In this regard, scientific societies and well-known companies involved in biotechnology are seeking to reach new methods for improvement of their product quality.
One of the most noticeable aspects of the advances is the improved efficacy of antibodies that particularly, in recent years, are used in treatment of cancers, autoimmune, and infectious diseases. Therefore, researchers have focused their studies to achieve this goal through modifications in genetic structures of antibodies and recombinant proteins.
Production of single chain antibodies (SCA) and their humanization are among the two techniques which are used for therapeutic and diagnostic purposes. Due to the small size of scFVs that are easier to penetrate into cancerous tissue, these molecules are optimal tools for diagnosis.
These antibodies which are firstly produced in mouse cannot be appropriately used in human body, but humanization of monoclonal antibodies by genetic engineering makes them more applicable for therapeutic purposes.
Main activities of the Research Group:
Group members:
Head of the Research Group: Dr. Hodjatollah Rabbani
One of the most noticeable aspects of the advances is the improved efficacy of antibodies that particularly, in recent years, are used in treatment of cancers, autoimmune, and infectious diseases. Therefore, researchers have focused their studies to achieve this goal through modifications in genetic structures of antibodies and recombinant proteins.
Production of single chain antibodies (SCA) and their humanization are among the two techniques which are used for therapeutic and diagnostic purposes. Due to the small size of scFVs that are easier to penetrate into cancerous tissue, these molecules are optimal tools for diagnosis.
These antibodies which are firstly produced in mouse cannot be appropriately used in human body, but humanization of monoclonal antibodies by genetic engineering makes them more applicable for therapeutic purposes.
Main activities of the Research Group:
- Creation of recombinant proteins with the aim of producing vaccines for prevention, treatment, and screening of diseases particularly cancer, autoimmune and infectious diseases
- Creation of single chain antibodies (SCAs) via genetic engineering for diagnostic and therapeutic purposes
- Humanization of antibodies through genetic engineering for treatment of diseases particularly cancer
- Molecular manipulation of antibodies and recombinant proteins to apply them in medicine and industry
- Production and application of new anti-cancer vaccines by analysis of expression profile data and selection of cancer cells markers
- Application of genetic engineering techniques for production of biological products used in cancer immunotherapy and other diseases
- Making animal models for cancer research to evaluate different methods of immunotherapy
- Introducing new tumor-associated antigens related to solid cancers and blood malignancies
Group members:
- Dr. Hodjatollah Rabbani
- Dr. Fatemeh Ghaemimanesh
- Mr. Ali Ahmad Bayat
- Dr. Soheila Arefi
- Dr. Maryam Yousefi
Head of the Research Group: Dr. Hodjatollah Rabbani
